Abnormalities, Multiple: Clinical Trials

31 trials for Abnormalities, Multiple, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 recruiting. 31 Phase 2, 5 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 231Recruiting 31
Phase 35Recruiting 5
Phase 13Recruiting 3

Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bempedoic Acid Therapy for Polycystic Kidney Disease
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s) - ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Phase 2RecruitingKenneth Hallows1202026-09-012026-09-29
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Mivelsiran, Placebo - Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Phase 2RecruitingAlnylam Pharmaceuticals582026-08-172026-11-18
Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome
Metric-optimized spectacles, Routine Clinical Spectacles - Refractive Error Correction, Visual Acuity
Phase 2RecruitingOhio State University242026-07-132026-07-20
KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome
CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE - POEMS Syndrome
Phase 2RecruitingShanghai Changzheng Hospital202026-06-152026-06-17
Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1
Tofacitinib Oral Solution, Placebo - Down Syndrome
Phase 2RecruitingUniversity of Colorado, Denver922026-05-282026-09-03
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
CSTI-500 - Prader-Willi Syndrome
Phase 2RecruitingConSynance Therapeutics122026-05-182026-10-21
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder
Phase 2RecruitingPaul Szabolcs252026-05-042026-05-15
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003 - Netherton Syndrome
Phase 2 / Phase 3RecruitingQuoin Pharmaceuticals162026-03-192026-09-28
CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease
investigating the role of CAIX as target in VHL disease and in VHL-/- tumors. - VHL - Von Hippel-Lindau Syndrome
Phase 2RecruitingIRCCS Ospedale San Raffaele382026-02-252026-03-09
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Abrocitinib - Atopic Dermatitis, Alopecia Areata
Phase 2RecruitingIcahn School of Medicine at Mount Sinai562026-01-122026-10-16
AEF0217 in Participants With Down Syndrome
AEF0217 100 µg, AEF0217 300 µg, Placebo - Down Syndrome (Trisomy 21)
Phase 2RecruitingAelis Farma1882025-12-222026-04-08
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
MVX-220 - Angelman Syndrome
Phase 1 / Phase 2RecruitingMavriX Bio, LLC122025-10-292026-07-24
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003, 4% Lotion - Netherton Syndrome
Phase 2 / Phase 3RecruitingQuoin Pharmaceuticals82025-10-062026-08-31
BCMA/CD3 BsAb Therapy for POEMS Syndrome
CM336 (BCMA/CD3 bispecific antibody) - POEMS Syndrome
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China102025-08-042026-09-29
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ABBV-CLS-628, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2RecruitingCalico Life Sciences LLC2402025-06-092026-10-06
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
JMKX003142 will be administered orally, Plcacebo - ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Phase 2RecruitingJemincare1352025-03-132025-07-03
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP)
Phase 1 / Phase 2RecruitingBlueRock Therapeutics542025-03-102026-10-15
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Tirzepatide, Placebo - Autosomal Dominant Polycystic Kidney, Obesity
Phase 2RecruitingUniversity of Colorado, Denver1262025-03-062025-05-06
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Sertraline, Placebo - Neurodevelopmental Disorders, Autism
Phase 2RecruitingHolland Bloorview Kids Rehabilitation Hospital1302024-09-162026-07-27
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment
Lithium Carbonate Capsule - Cornelia De Lange Syndrome
Phase 2 / Phase 3RecruitingUniversity of Milan342024-05-012025-01-28

Showing 20 of 31. Sign in to see all of them.

Narrower conditions

Down Syndrome (10)  ·  Polycystic Kidney, Autosomal Dominant (5)  ·  von Hippel-Lindau Disease (4)  ·  Alzheimer Disease (3)  ·  Netherton Syndrome (3)  ·  Cognitive Dysfunction (2)  ·  DiGeorge Syndrome (2)  ·  Neuroectodermal Tumors, Primitive (2)  ·  POEMS Syndrome (2)  ·  Paraganglioma (2)  ·  Pheochromocytoma (2)  ·  22q11 Deletion Syndrome (1)  ·  Adenoma, Islet Cell (1)  ·  Alopecia Areata (1)  ·  Angelman Syndrome (1)

Broader conditions

Congenital Abnormalities (31)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (31)  ·  Genetic Diseases, Inborn (29)  ·  Nervous System Diseases (21)  ·  Chromosome Disorders (15)  ·  Neurologic Manifestations (14)  ·  Intellectual Disability (13)  ·  Neurobehavioral Manifestations (13)  ·  Ciliopathies (9)  ·  Cardiovascular Diseases (6)  ·  Female Urogenital Diseases (6)  ·  Female Urogenital Diseases and Pregnancy Complications (6)  ·  Kidney Diseases (6)  ·  Male Urogenital Diseases (6)

Interventions

Dexamethasone (2)  ·  belzutifan (2)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1)  ·  Asparaginase (1)  ·  Biopsy (1)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Cytarabine (1)  ·  Gonadotropin-Releasing Hormone (1)  ·  Hydrocortisone (1)  ·  Leuprolide (1)  ·  Lithium Carbonate (1)  ·  Mercaptopurine (1)  ·  Methotrexate (1)  ·  N,N-dicyclohexyl-isoborneol-10-sulfonamide (1)

Sponsors

Quoin Pharmaceuticals (3)  ·  National Cancer Institute (NCI) (2)  ·  University of Colorado, Denver (2)  ·  AC Immune SA (1)  ·  Aelis Farma (1)  ·  Alnylam Pharmaceuticals (1)  ·  BlueRock Therapeutics (1)  ·  Brigham and Women's Hospital (1)  ·  Calico Life Sciences LLC (1)  ·  ConSynance Therapeutics (1)  ·  EspeRare Foundation (1)  ·  Holland Bloorview Kids Rehabilitation Hospital (1)  ·  IRCCS Ospedale San Raffaele (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)

Countries

United States (21)  ·  Italy (6)  ·  Spain (6)  ·  United Kingdom (5)  ·  Canada (4)  ·  China (4)  ·  France (4)  ·  Australia (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Japan (2)  ·  Portugal (2)  ·  South Korea (2)  ·  Belgium (1)  ·  Brazil (1)

Top investigators

Aglaia Vignoli, Professor, MD (1)  ·  Alexander C Conley, Ph.D. (1)  ·  Dana Miskulin, MD (1)  ·  Dr. Evdokia Anagnostou (1)  ·  Dusan Bogunovic, PhD (1)  ·  Emma Guttman, MD (1)  ·  Haiyan He, Dr. (1)  ·  Holm Schneider, MD (1)  ·  Hong Zhang, Ph.D (1)  ·  Joaquin Espinosa, PhD (1)  ·  Kenneth R Hallows, MD, PhD, FASN (1)  ·  Michael Rafii, MD (1)  ·  Naris Nilubol, M.D. (1)  ·  Nelly Pitteloud, MD (1)

Results publications

PMID 41348481, PMID 41385299, PMID 35622074, PMID 36048943, PMID 41124218, PMID 41671463

NIH funding

2023 (1), 2025 (1), R01DK138915 (1), R01EY024590 (1), R61AR084210 (1), U10CA180886 (1)